TABLE 3.
cDNA fragments identified by differential display in the biopsy of the PPD site
| cDNA band | Regulation with IL-2 PPD site | Primers | Sequence homology | Regulation with IL-2c
|
|
|---|---|---|---|---|---|
| Patient PBMC in vivoa | Control PBMC in vitrob | ||||
| K26 | Up | DD2, OPA20 | CD63 | No | ND |
| B1 | Down | DD1, OPA18 | β-Adaptin | No | ND |
| B7a | Up | DD2, OPA18 | hnRNP G protein | No | Yes |
| B7b | Up | DD2, OPA18 | Cytochrome oxidase I | No | Yes |
| B17/B20d | Up | DD3, DD1, OPA18 | Clathrin heavy chain | Yes | Yes |
| B23 | Down | DD1, OPA20 | Human cDNA | Yes | ND |
| B26 | Down | DD2, OPA18 | Human cDNA | Yes | ND |
| B27 | Down | DD2, AP4 | Human cDNA | Yes | ND |
| B24e | No | DD2, OPA14 | Human cDNA | Yes | ND |
a
PBMC not stimulated in vitro.
b
PBMC stimulated in vitro; genes induced by M. tuberculosis and further up-regulated by rhuIL-2.
c
No, no effect; Yes, either up- or down-regulated; ND, not done.
d
Gene identified independently in the patient PPD skin test site, where it is up-regulated in response to rhuIL-2 administration, and in patient PBMC, where it is down-regulated in response to rhuIL-2 administration.
e
Gene not identified by differential display at the PPD skin test site but down-regulated in PBMC in response to rhuIL-2 treatment.